Acute myeloid leukemia
Recent developments in immunotherapy of acute myeloid leukemia
... of acute myeloid leukemia (AML) is hampered by various characteristics of the disease, including non-leukemia-restricted target antigen expression profile, low endogenous immune responses, and ...
20
Aberrant phenotypes in acute myeloid leukemia in India
... The study included 35 samples of newly diagnosed acute myeloid leukemia. Patients age ranged from 15-80 years with the mean age of 40.65 years. The male to female ratio was 1.9:1. Based on ...
5
Emerging therapies for acute myeloid leukemia
... Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity. Despite the advances in our understanding of its pathobiology, the chemotherapy-directed management has ...
14
Targeting mitochondrial RNA polymerase in acute myeloid leukemia
... AML, acute myeloid leukemia; ATP5A, ATP synthase subunit alpha, mitochondrial; ATP8, ATP synthase protein 8; BFU-E, burst forming units-erythroid; CFU-Eo, colony forming units-eosinophil; CFU-G, ...
13
Molecular targeting in acute myeloid leukemia
... AML: acute myeloid leukemia; FLT3: FMS-like tyrosine kinase 3; DNMT: DNA methyltransferase; TET: ten-eleven-translocation; IDH: isocitrate dehydro- genase; HDAC: histone deacetylase; BET: bromodomain ...
13
Acute Myeloid Leukemia Therapeutics Market to 2020
... 4: Acute Myeloid Leukemia Therapeutics, Response Criteria (Remission or Treatment Failure) Table 5: Acute Myeloid Leukemia Therapeutics, Survival and Relapse Rates by Risk ...
8
BEX1 acts as a tumor suppressor in acute myeloid leukemia
... with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detec- tion of minimal residual ...
11
Clinicopathologic Analysis of Acute Myeloid Leukemia in a Single Institution: Biphenotypic Acute Myeloid Leukemia May Not Be an Aggressive Subtype
... Most acute leukemias are classified as lymphoid or myeloid lineages by standard microscopic morphology, cytochemistry and a panel of immunologic ...of acute leukemia incor- porates ...
5
Advances in the drug therapies of acute myeloid leukemia (except acute promyelocytic leukemia)
... Abstract: Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy, characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other ...
9
The Development of Personalized Medicine: Acute Myeloid Leukemia as a Model
... in acute myeloid ...diagnosing acute myeloid leukemia, whereas as molecular genetics/genomics (C), cytogenetics (D), flow cytometry (E) are of highly important for subtype ...
12
Aspergillosis in a Child with Acute Myeloid Leukemia: Complications, and Treatment
... periodic weakening of the immune system. Prophylactic use of antibacterial and antifungal agents in children undergoing treatment for acute myeloid leukemia (AML) has been advocated. [4] Invasive ...
5
Scopulariopsis Brevicaulis Infection in a Patient with Acute Myeloid Leukemia
... Scopulariopsis Brevicaulis Infection in a Patient with Acute Myeloid Leukemia CASE REPORT Scopu/ar;ops;s Brev;cau/;s Infection in a Patient with Acute Myeloid Leukemia 111111 , K P Ng, Ph D*, T S Soo[.] ...
5
Aberrant phenotypes in acute myeloid leukemia in India.
... of acute leukemia classification and is considered particularly useful for identifying poorly differentiated subtypes of acute leukemia, acute myeloid leukemia (AML) with ...
136
FOXM1 contributes to treatment failure in acute myeloid leukemia
... Acute myeloid leukemia (AML) patients with NPM1 mutations demonstrate a superior response to standard chemotherapy ...FLT3-ITD–driven myeloid neoplasm in a FOXM1-overexpressing transgenic ...
18
Role of CXCR4 in the Pathogenesis of Acute Myeloid Leukemia
... Acute myeloid leukemia (AML) is a heteroge- neous group of diseases characterized by the uncon- trolled proliferation of hematopoietic stem cells and progenitors (blasts) with a reduced capacity to ...
6
Molecular landscape and targeted therapy of acute myeloid leukemia
... AML: Acute myeloid leukemia; ASXL1: Additional sex comb-like 1; BCL-2: B-cell CLL/lymphoma 2; CAR-T: Chimeric antigen receptor T; CBF-AML: Core-binding factor AML; CEBPA: CCAAT/enhancer binding ...
8
Recent drug approvals for acute myeloid leukemia
... 1: Myeloid cell leukemia-1; MDS: Myelodysplastic syndrome; MEC: Mitoxantrone, etoposide and cytarabine; MPN: Myeloproliferative neoplasms; MRD: Minimal residual disease; NPM1: Nucleophosmin 1; NR: Not ...
20
Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
... 34. Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Stasi AD, Stuart R, Olin R, Kasner M, Ciceri F, Chou W-C, Podoltsev N, Recher C, Yokoyama H, ...
6
Acute Myeloid Leukemia
... AML Treatment in Older Adults. Acute myeloid leukemia occurs more frequently with advancing age. At least half of patients are older than 65 years of age when the disease is diagnosed. Today there ...
56
GENETIC PROGNOSTIC FACTORS IN ACUTE MYELOID LEUKEMIA
... Acute myeloid leukemia (AML) is a disorder of myeloid hematopoietic stem cells (HSC) with the presence of more than 20% of myeloid blast cells in the bone ...other myeloid clonal ...
87